Day One Biopharmaceuticals, Inc.

Contributing Author

Recent Articles by Day One Biopharmaceuticals, Inc.

Jan-11	Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance DAWN GlobeNewswire
Jan-06	Day One Completes Acquisition of Mersana Therapeutics DAWN GlobeNewswire
Dec-16	Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference DAWN GlobeNewswire
Nov-24	Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting DAWN GlobeNewswire
Nov-18	Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference DAWN GlobeNewswire
Nov-13	Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases DAWN GlobeNewswire
Nov-10	Day One Announces New OJEMDA (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting DAWN GlobeNewswire
Nov-04	Day One Reports Third Quarter 2025 Financial Results and Corporate Progress DAWN GlobeNewswire
Oct-21	Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 DAWN GlobeNewswire
Aug-05	Day One Reports Second Quarter 2025 Financial Results and Corporate Progress DAWN GlobeNewswire
Jul-22	Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 DAWN GlobeNewswire
Jun-10	Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development DAWN GlobeNewswire
May-06	Day One Reports First Quarter 2025 Financial Results and Corporate Progress DAWN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.